Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
Approval is based on results from the phase 3 OASIS 4 clinical trial
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
